Amanzada, Ahmad

[["dc.bibliographiccitation.firstpage","e0233811"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Knoop, Richard"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Pilavakis, Yiannis"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.editor","Bonaz, Bruno"],["dc.date.accessioned","2021-04-14T08:25:13Z"],["dc.date.available","2021-04-14T08:25:13Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1371/journal.pone.0233811"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17632"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81557"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1932-6203"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e25111"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Medicine"],["dc.bibliographiccitation.volume","100"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Burmester, Merle"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Pilavakis, Yiannis"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Amanzada, Ahmad"],["dc.date.accessioned","2021-06-01T10:47:00Z"],["dc.date.available","2021-06-01T10:47:00Z"],["dc.date.issued","2021"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.1097/MD.0000000000025111"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17849"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85446"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1536-5964"],["dc.relation.issn","0025-7974"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","123"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Gastroenterology"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Tsaknakis, Birgit"],["dc.contributor.author","Masri, Rawan"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Kunsch, Steffen"],["dc.date.accessioned","2019-07-09T11:45:36Z"],["dc.date.available","2019-07-09T11:45:36Z"],["dc.date.issued","2018"],["dc.description.abstract","BACKGROUND: The mortality due to hemorrhage of esophageal varices (EV) is still high. The predominant cause for EV is liver cirrhosis, which has a high prevalence in Western Europe. Therefore, non-invasive screening markers for the presence of EV are of interest. Here, we aim to investigate whether non-inflammatory gall bladder wall thickening (GBWT) may serve as predictor for the presence of EV in comparison and combination with other non-invasive clinical and laboratory parameters. METHODS: One hundred ninety four patients were retrospectively enrolled in the study. Abdominal ultrasound, upper endoscopy and blood tests were evaluated. GBWT, spleen size and the presence of ascites were evaluated by ultrasound. Platelet count and Child-Pugh-score were also recorded. The study population was categorized in two groups: 122 patients without esophageal varices (non EV) compared to 72 patients with EV were analyzed by uni-and multivariate analysis. RESULTS: In the EV group 46% showed a non-inflammatory GBWT of ≥4 mm, compared to 12% in the non-EV group (p < 0.01). GBWT was significantly higher in EV patients compared to the non-EV group (mean: 4.4 mm vs. 2.8 mm, p < 0.0001), and multivariate analysis confirmed GBWT as independent predictor for EV (p < 0.04). The platelets/GBWT ratio (cut-off > 46.2) had a sensitivity and specificity of 78 and 86%, PPV 76% and NPV of 87%, and ROC analysis calculated the AUC of 0.864 (CI 0.809-0.919). CONCLUSIONS: GBWT occurs significantly more often in patients with EV. However, because of the low sensitivity, combination with other non-invasive parameters such as platelet count is recommended."],["dc.identifier.doi","10.1186/s12876-018-0852-5"],["dc.identifier.pmid","30071840"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15253"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59263"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","BioMed Central"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Gall bladder wall thickening as non-invasive screening parameter for esophageal varices – a comparative endoscopic – sonographic study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","367"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Clinical Ultrasound"],["dc.bibliographiccitation.lastpage","374"],["dc.bibliographiccitation.volume","50"],["dc.contributor.affiliation","Bremer, Sebastian C. B.; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Knoop, Richard F.; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Porsche, Melissa; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Amanzada, Ahmad; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Ellenrieder, Volker; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Neesse, Albrecht; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Kunsch, Steffen; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.author","Bremer, Sebastian C. B."],["dc.contributor.author","Knoop, Richard F."],["dc.contributor.author","Porsche, Melissa"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Petzold, Golo"],["dc.date.accessioned","2021-12-01T09:23:12Z"],["dc.date.available","2021-12-01T09:23:12Z"],["dc.date.issued","2021"],["dc.date.updated","2022-06-14T22:49:32Z"],["dc.description.abstract","Abstract Purpose Increased gallbladder wall thickness (GBWT) is a common finding. Reported causes include advanced chronic liver disease (ACLD), ascites and hypalbuminemia. GBWT is a marker for the prediction of esophageal varices. It remains unclear which of these factors is the decisive driver of GBWT. We aim to investigate whether there is a predominant factor associated with the GBWT. Methods We enrolled 258 patients with ascites, hypalbuminemia and/or ACLD and 98 healthy volunteers that underwent abdominal ultrasound. Differences of mean GBWT in subgroups of patients with ACLD, ascites, and/or hypalbuminemia were analyzed. Correlation between various parameters and GBWT were calculated using multiple regression analysis. Results GBWT in patients with ACLD + ascites + hypalbuminemia (n = 59; 5.70 ± 2.05 mm) was pathologically increased compared to patients with hypalbuminemia + ascites without ACLD (n = 36; 2.14 ± 0.66 mm; p < .001) and to patients with only hypalbuminemia (n = 76; 2.02 ± 0.80 mm; p < .001). GBWT of patients with ACLD + hypalbuminemia (n = 30; 3.42 ± 1.52 mm) and with ACLD and normal albumin level were not different (n = 46; 3.10 ± 1.62 mm; p > .999). Significant correlation was seen between GBWT and ACLD (r = .53; p < .001) and ascites (r = .51; p < .001) but not albumin level (r = .04; p = .510). Conclusion We demonstrate that ACLD is predominantly associated with GBWT. In contrast to the current literature, serum albumin level appears not to be associated with pathological GBWT."],["dc.description.abstract","Representative image of a gallbladder of a patient with liver cirrhosis and ascites using a convex transducer (4.0 MHz). The gallbladder wall is pathologically thickened image"],["dc.identifier.doi","10.1002/jcu.23077"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/94586"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-478"],["dc.publisher","John Wiley & Sons, Inc."],["dc.relation.eissn","1097-0096"],["dc.relation.issn","0091-2751"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited."],["dc.title","Pathological gallbladder wall thickening is associated with advanced chronic liver disease and independent of serum albumin"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e0223893"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Bathe, Anna Luisa"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.editor","Bonaz, Bruno"],["dc.date.accessioned","2020-12-10T18:42:11Z"],["dc.date.available","2020-12-10T18:42:11Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1371/journal.pone.0223893"],["dc.identifier.eissn","1932-6203"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16609"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77836"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn’s disease and ulcerative colitis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e000258"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMJ Open Gastroenterology"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Ternes, Kristin"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Bremer, Sebastian Christopher Benjamin"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Amanzada, Ahmad"],["dc.date.accessioned","2019-07-09T11:50:10Z"],["dc.date.available","2019-07-09T11:50:10Z"],["dc.date.issued","2019"],["dc.description.abstract","Background Concurrent cytomegalovirus (CMV) colitis in inflammatory bowel disease (IBD) and after haematopoietic stem cell transplantation (HSCT) is an important clinical entity associated with high rates of morbidity and mortality. Methods A retrospective study of 47 patients with IBD and 61 HSCT patients was performed regarding the evaluation of diagnostic accuracy of applied methods, predictors, risk factors for CMV disease manifestation, the proportion of patients with antiviral treatment and disease outcome. Results The sensitivity of quantitative PCR (qPCR) with a cut-off value of >250 copies/mg for CMV colitis in patients with IBD and HSCT patients was 79% and 92%, respectively. Predictors for CMV colitis in the IBD cohort were anaemia and the presence of endoscopic ulcers. Glucocorticoids, calcineurin inhibitors and >2 concurrent lines of treatment with immunosuppressive drugs could be identified as risk factors for CMV colitis in the IBD cohort with an OR of 7.1 (95% CI 1.7 to 29.9), 21.3 (95% CI 2.4 to 188.7) and 13.4 (95% CI 3.2 to 56.1), respectively. Predictors and risk factors for CMV gastroenteritis in the HSCT cohort was the presence of endoscopic ulcers (OR 18.6, 95% CI 3.3 to 103.7) and >2 concurrent lines of treatment with immunosuppressive drugs. Antiviral therapy was administered in 70% of patients with IBD and 77% of HSCT patients with CMV disease. 71% of antiviraltreated patients with IBD showed an improvement of their disease activity and 14% underwent colectomy. The mortality rate of HSCT patients was 21% irrespective of their CMV status. Conclusions In addition to the implementation of histological methods, qPCR may be performed in patients with suspected high-risk IBD and HSCT patients for CMV colitis. Independent validations of these results in further prospective studies are needed."],["dc.identifier.doi","10.1136/bmjgast-2018-000258"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15876"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59717"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Cytomegalovirus colitis in inflammatory bowel disease and after haematopoietic stem cell transplantation: diagnostic accuracy, predictors, risk factors and disease outcome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e15172"],["dc.bibliographiccitation.firstpage","e15172"],["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Medicine"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Amanzada, Ahmad"],["dc.date.accessioned","2020-12-10T18:20:07Z"],["dc.date.available","2020-12-10T18:20:07Z"],["dc.date.issued","2019"],["dc.description.abstract","The incidence of inflammatory bowel disease (IBD) is increasing and the pathogenesis is still not completely understood. Micronutrients like vitamin D [25 (OH)D] and zinc play an important role in enzyme activities and the immune system. As the 25 (OH)D-receptor has been shown to be downregulated in patients with IBD, 25 (OH)D may emerge as a predictive marker for disease improvement. Studies on relationship of both micronutrients in IBD patients are lacking.We retrospectively evaluated serum levels of 25(OH)D and zinc together with baseline characteristics of 232 IBD patients. Uni- and multivariate analyses were performed for association between serum levels of 25(OH)D and zinc with clinical and deep remission (CR and DR).155 Crohn's disease (CD) and 77 ulcerative colitis (UC) patients were included. 54% (n = 125) and 6% (n = 14) of IBD patients showed deficient serum 25(OH)D levels below 20 ng/mL and zinc levels below 7 μmol/L. Serum 25(OH)D levels were significantly higher in IBD patients with CR (P = .02) and DR (P < .001) but not serum zinc levels, respectively. Serum 25(OH)D levels (P = .008), anti-tumor-necrosis-factor-α-trough-concentration (anti-TNF-α-TC) (P = .02) and CRP level (P = .02) were independently associated with CR in CD patients. Serum 25(OH)D threshold of 19 ng/mL discriminated CD patients with or without CR, having an area under the receiver operating curve analysis (AUROC) of 0.77 [95%-confidence interval (CI): 0.68-0.85]. In multivariate analysis serum 25(OH)D levels (P = .04) and anti-TNF-α-TC (P = .04) were associated with DR in CD patients. Serum 25(OH)D threshold of 26 ng/mL discriminated CD patients with or without DR, having an AUROC of 0.75 (95%-CI: 0.68-0.83).Serum 25(OH)D (P = .04) and fecal calprotectin levels (P = .04) were independently correlated with CR in UC patients. Serum 25(OH)D threshold of 32 ng/mL discriminated UC patients in CR with an AUROC of 0.83 (95%-CI: 0.71-0.95). Zinc levels did not correlate with disease activity status in CD or UC patients either.In conclusion, beside CRP and fecal calprotectin, serum 25(OH)D levels, but not serum zinc levels, may be an additional useful and noninvasive marker for characterizing different disease activity status of IBD patients. Measurement of serum 25(OH)D in IBD patients may be warranted. 25(OH)D supplementation in deficient IBD patients is recommended."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2019"],["dc.identifier.doi","10.1097/MD.0000000000015172"],["dc.identifier.eissn","1536-5964"],["dc.identifier.issn","0025-7974"],["dc.identifier.pmid","30985701"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16069"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75459"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1536-5964"],["dc.relation.issn","0025-7974"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Serum vitamin D but not zinc levels are associated with different disease activity status in patients with inflammatory bowel disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","BioMed Research International"],["dc.bibliographiccitation.lastpage","6"],["dc.bibliographiccitation.volume","2022"],["dc.contributor.author","Knoop, Richard F."],["dc.contributor.author","Gaertner, Pauline C."],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Bremer, Sebastian C. B."],["dc.contributor.author","Kunsch, Steffen"],["dc.date.accessioned","2022-06-01T09:39:38Z"],["dc.date.available","2022-06-01T09:39:38Z"],["dc.date.issued","2022"],["dc.description.abstract","Background and Aims. In contrast to guideline recommendations, endoscopic testing for Helicobacter pylori is frequently performed under Helicobacter pylori suppressive conditions, e.g., intake of proton-pump inhibitors (PPI), preceded antibiotic treatment, or recent gastrointestinal bleeding. Our study\\’s aim was to retest patients with—under suppressive conditions—negative test results. This was carried out in order to examine the rate of false negative tests previously gathered under suppressive conditions. Methods. The trial was conducted in a large patient collective in a university hospital. Every elective esophagogastroduodenoscopy from in- and outpatients was included. Prior to endoscopy, suppressive conditions were collected via standardized questionnaire. If Helicobacter pylori testing was indicated, both helicobacter urease test and histology were performed in analogy to the Sydney classification. In case of a negative result under suppressive conditions, the patient was reinvited after, if possible, withdrawal of suppressive condition in order to perform a urea breath test (UBT). Results. 1,216 patients were included (median 59 years, 72.0% inpatients, 28.0% outpatients). Overall, 60.6% (737) were under Helicobacter pylori suppressive conditions. The main suppressive condition was intake of PPIs (54.5%). In 53.7% (653) of all included cases, Helicobacter pylori testing was performed. Of those, 14.1% (92) had a positive test, and 85.9% (561) were negative. Out of the patients with negative result, 50.8% (285) were tested under suppressive conditions and consequently invited for retesting via UBT. In 20.4% (45), suppressive conditions could not be ceased. In 22.8% (65), retesting was conducted. Of those, 98.5% (64) congruently presented a negative result again, and only 1.5% (1) was positive for Helicobacter pylori. Conclusion. Many patients undergoing esophagogastroduodenoscopy in everyday clinical practice are tested for Helicobacter pylori under suppressive conditions leading to a potentially higher risk of false negative results. However, our research shows that this issue might be overestimated."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.1155/2022/5380001"],["dc.identifier.pii","5380001"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108523"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-572"],["dc.relation.eissn","2314-6141"],["dc.relation.issn","2314-6133"],["dc.rights","CC BY 4.0"],["dc.title","Systematic Retesting for Helicobacter pylori: The Potential Overestimation of Suppressive Conditions"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","552"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Digestion"],["dc.bibliographiccitation.lastpage","556"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Knoop, Richard F."],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Bremer, Sebastian C.B."],["dc.contributor.author","Gress, Thomas M."],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Kunsch, Steffen"],["dc.date.accessioned","2021-04-14T08:32:51Z"],["dc.date.available","2021-04-14T08:32:51Z"],["dc.date.issued","2020"],["dc.description.abstract","Background and Aims: Testing for Helicobacter pylori is frequently conducted during esophagogastroduodenoscopy (EGD). Suppressive conditions such as the intake of proton-pump inhibitors (PPIs), preceded antibiotic treatment or recent upper gastrointestinal bleeding impair H. pylori test quality. The aim of our study was to evaluate the frequency and pattern of H. pylori suppressive conditions in a large patient collective undergoing elective EGD in a German university hospital. Methods: The trial was performed as a single-center study. Only elective EGD from inpatients and outpatients were included. Prior to endoscopy, H. pylori suppressive conditions were collected using a standardized questionnaire. If H. pylori testing was indicated according to the guidelines, always both histology and helicobacter urease test were performed in analogy to the Sydney classification. Results: One thousand six hundred and thirty-one patients were included (median 61 years, 36.0% outpatients, 64.0% inpatients). Overall, 76.5% of patients were under H. pylori suppressive conditions. The main suppressive condition was the intake of PPIs (70.7%). In 819 (50.2%) of all included cases, H. pylori testing was performed. The following were the results: 17.3% (142) had a positive H. pylori testing and 82.7% (677) were negative. Of those with negative result, 70.0% were tested under suppressive conditions. Conclusion: Guidelines recommend H. pylori testing under non-suppressive conditions. However, this does not always meet the clinical practice. Our data show that de facto, many patients undergoing elective EGD are tested for H. pylori under suppressive conditions coming along with a higher risk of potentially false negative results. Particularly, concerning this issue, further research is needed to improve and clarify everyday clinical practice."],["dc.identifier.doi","10.1159/000501270"],["dc.identifier.pmid","31216545"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/84034"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1421-9867"],["dc.relation.issn","0012-2823"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","Testing of Helicobacter pylori by Endoscopic Biopsy: The Clinical Dilemma of Suppressive Conditions"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]